Cambridge Healthtech Institute’s 2nd Annual

Covalent Chemistries & Induced Proximity

Utilizing and Manipulating Protein Binding and Cellular Interactions to Drive New Therapies

September 22, 2025 ALL TIMES EDT

A new generation of drug modalities is being developed to leverage the cellular machinery to disrupt protein-protein interactions (PPI), to induce proximity between key cellular components and to seek out previously “undruggable” targets for therapeutic intervention. Cambridge Healthtech Institute’s symposium focused on Covalent Chemistries & Induced Proximity brings together experts to discuss innovative chemistry, complex cell biology, and novel techniques that are opening avenues for tackling difficult drugs targets and exploring previously untapped cellular mechanisms for drug discovery.

Monday, September 22

8:00 amPre-Conference Symposium Registration Open and Morning Coffee

8:50 amWelcome Remarks

EXPLORING INDUCED PROXIMITY

8:55 am

Chairperson's Remarks

Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation

9:00 am

An ‘Omics Approach for Drug Discovery

Stefan Harry, PhD, ACS Postdoctoral Fellow, Harvard University and Massachusetts General Hospital

We developed DrugMap, a cysteine reactivity atlas across 416 cancer cell lines, uncovering context-specific ligandability driven by redox, conformation, and genetics. This enabled covalent targeting of NFκB1 and SOX10. We further introduced molecular COUPLrs—dual warhead ligands—and CONNECT proteomics, revealing hundreds of inducible protein couplings. A COUPLr targeting EML4-ALK disrupted signaling. Together, these tools map and reprogram protein interactions to access undruggable cancer targets.

10:00 am

Cereblon: The Gift That Keeps On Giving

Katherine Donovan, PhD, Scientist, Laboratory of Dr. Eric Fischer, Cancer Biology, Dana-Farber Cancer Institute/Harvard Medical School

Small molecules inducing protein degradation via ligase-mediated ubiquitylation are promising in pharmacology. To comprehensively explore the target space of CRBN, we developed a sensitive and high-throughput lysate-based IP-MS pipeline for unbiased identification of molecular glue targets of IMiD-CRBN. Our study offers a broad catalog of CRBN-recruited targets (>290 targets) and introduces a scalable workflow for discovering new drug-induced protein interactions in cell lysates.

10:30 amQ&A with Session Speakers

11:00 amEnjoy Lunch on Your Own

COVALENT DRUG DISCOVERY

12:30 pm

The Other Half of the Reactive Proteome and a New Era for Drug Targets and Functional Activity-based Proximity Chemistry

Megan Matthews, PhD, Assistant Professor, Department of Chemistry, University of Pennsylvania

1:00 pm

Enabling Covalent Drug Discovery by Chemical Biology and Proteomics

Hua Xu, PhD, Director, Head of Chemical Biology and Proteomics, AstraZeneca

Covalent modulation of therapeutic targets is an increasingly important modality for drug discovery, particularly after recent success with historically challenging targets like KRAS G12C. In this talk, I’ll present the work we have done to discover covalent inhibitors for two different targets, and also describe the chemical biology approaches to understand the selectivity and mechanisms of action of these inhibitors.

1:30 pm

Rewiring Cancer Drivers to Activate Programmed Cell Death

Isabella Graef, MD, CEO, Shenandoah Therapeutics

Sushant Malhotra, PhD, Senior Vice President, Drug Discovery, Shenandoah Therapeutics

Nearly every cancer is driven by unique cancer drivers. Each cancer cell has inherent self-destruct mechanisms leading to cell death. Despite being genetically validated, many oncogenic drivers are hard to target with drugs. We have created small molecules (TCIPs) that employ chemically induced proximity to trigger potent and specific cell death pathways dependent on the mutated cancer driver. This feature confers upon TCIPs an exquisite specificity in killing cancer cells.

2:00 pmIn-Person Brainstorming Session

This informal session will be led by the speakers, allowing participants to ask questions and exchange ideas around topics related to the symposium. To get the most out of this session, please come prepared to share your ideas and participate in collective problem solving.

2:45 pmNetworking Refreshment Break

Join your colleagues for a cup of coffee or refreshments and make new connections​

3:15 pm

COOKIE-Pro: Covalent Inhibitor Binding Kinetics Profiling on the Proteome Scale

Jin Wang, PhD, Director, Biochemistry and Molecular Pharmacology, Baylor College of Medicine

We developed COOKIE-Pro, a new method to quantify the binding kinetics of covalent inhibitors across the entire proteome. Using mass spectrometry, it determines kinetic values (kinact?/KI?) for both on- and off-target proteins. We validated COOKIE-Pro with BTK inhibitors, reproducing known parameters and identifying novel off-targets. This powerful tool helps optimize the potency and selectivity of covalent drugs, aiding preclinical development by providing a comprehensive view of inhibitor binding.

3:45 pm

Going beyond Cysteine for Kinase Covalent Ligand Discovery

Ken Hsu, PhD, Stephen F. and Fay Evans Martin Endowed Associate Professor, Department of Chemistry, The University of Texas at Austin

I will describe sulfonyl-triazoles as an enabling electrophile for developing covalent binders to tyrosine and lysine residues on proteins through sulfur-triazole exchange (SuTEx) chemistry. SuTEx chemistry is highly tunable with respect to protein reactivity and specificity, which can facilitate optimization of potent and selective binders to orthosteric and allosteric sites on kinases. I will conclude my talk by describing efforts to apply SuTEx ligands for modulating kinase function in cells.

4:15 pmClose of Symposium

5:00 pmDinner Short Courses*

*All Access Package or separate registration required. See Short Courses page for details.

7:30 pmClose of Day





No Agenda API URL configured.

Register Today